Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Edwards

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Antimicrobial Agents and Chemotherapy|July 31, 2025
Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and <i>Pseudomonas aeruginosa</i> in a 7-day hollow fiber infection modelLindsay M Avery, Mitchell Edwards, Fan Yi, et al.
Digestive Diseases and Sciences|October 21, 2020
Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and AnticoagulantsAhmad M Al-Taee, Elie Ghoulam, Preston Lee, et al.
Gastroenterology Research|November 23, 2020
Cervical Cancer Screening in Inflammatory Bowel Disease: Who Should Be Screening?Anuj Chhaparia, Florence Odufalu, Mitchell Edwards, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2025
Impact of porin deletions on cefepime-taniborbactam activity against <i>Klebsiella pneumoniae</i>Tsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2025
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic <i>Escherichia coli</i> strainsTsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, et al.
JCO Oncology Practice|June 17, 2026
Patient Perspectives on and Willingness to Pay for Navigation Services Billed Under Centers for Medicare & Medicaid Services Principal Illness Navigation CodesCourtney P Williams, Jessica Shuey, Nicole L Henderson, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2025
<i>Burkholderia pseudomallei</i> PenI β-lactamase and variants are potently inhibited by taniborbactamMaria F Mojica, Scott A Becka, Mitchell Edwards, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 31, 2019
ULK2 is essential for degradation of ubiquitinated protein aggregates and homeostasis in skeletal muscleJordan D Fuqua, Caleb P Mere, Ana Kronemberger, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
A new class of penicillin-binding protein inhibitors to address drug-resistant <i>Neisseria gonorrhoeae</i>Tsuyoshi Uehara, Allison L Zulli, Brittany Miller, et al.
Nature Microbiology|April 8, 2026
A penicillin-binding protein inhibitor series to target drug-resistant Neisseria gonorrhoeaeTsuyoshi Uehara, Allison L Zulli, Brittany Miller, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Antimicrobial Agents and Chemotherapy|July 31, 2025
Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and <i>Pseudomonas aeruginosa</i> in a 7-day hollow fiber infection modelLindsay M Avery, Mitchell Edwards, Fan Yi, et al.
Digestive Diseases and Sciences|October 21, 2020
Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and AnticoagulantsAhmad M Al-Taee, Elie Ghoulam, Preston Lee, et al.
Gastroenterology Research|November 23, 2020
Cervical Cancer Screening in Inflammatory Bowel Disease: Who Should Be Screening?Anuj Chhaparia, Florence Odufalu, Mitchell Edwards, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2025
Impact of porin deletions on cefepime-taniborbactam activity against <i>Klebsiella pneumoniae</i>Tsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2025
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic <i>Escherichia coli</i> strainsTsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, et al.
JCO Oncology Practice|June 17, 2026
Patient Perspectives on and Willingness to Pay for Navigation Services Billed Under Centers for Medicare & Medicaid Services Principal Illness Navigation CodesCourtney P Williams, Jessica Shuey, Nicole L Henderson, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2025
<i>Burkholderia pseudomallei</i> PenI β-lactamase and variants are potently inhibited by taniborbactamMaria F Mojica, Scott A Becka, Mitchell Edwards, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 31, 2019
ULK2 is essential for degradation of ubiquitinated protein aggregates and homeostasis in skeletal muscleJordan D Fuqua, Caleb P Mere, Ana Kronemberger, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
A new class of penicillin-binding protein inhibitors to address drug-resistant <i>Neisseria gonorrhoeae</i>Tsuyoshi Uehara, Allison L Zulli, Brittany Miller, et al.
Nature Microbiology|April 8, 2026
A penicillin-binding protein inhibitor series to target drug-resistant Neisseria gonorrhoeaeTsuyoshi Uehara, Allison L Zulli, Brittany Miller, et al.
Pageof 1